SciClone will develop and distribute Tasfygo in greater China but Eisai will retain worldwide rights outside the region.

Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions.

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic ...

Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive ...

Panelists discuss how clinical and patient-specific factors, such as comorbidities, age, and risk profiles, influence the selection of Bruton tyrosine kinase (BTK) inhibitors for treatment-naive ...

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors have transformed the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), especially in ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

This important study uses advanced computational methods to elucidate how environmental dielectric properties influence the interaction strengths of tyrosine and phenylalanine in biomolecular ...

“L-tyrosine is a precursor to dopamine, the neurotransmitter that aids in motivation, mood regulation, and pleasure,” says ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from ...

Sheridan, Wyoming - Brighter A.M., an emerging leader in wellness nutrition, announced the launch of its flagship product, ...

Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...